CD274 and triple-negative breast carcinoma: The inhibition of PD-L1 with monoclonal antibody (H1A) sensitizes human triple-negative breast cancer cells to cisplatin in vitro and in vivo [99], suggesting that the combination of the drug with anti-PD-L1 treatments may enhance the therapeutic efficacy of chemotherapeutic drug alone [9,194,195], at least in mouse tumor models.